Orphan designation: (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one (duvelisib), Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma

2019 ◽  
Author(s):  
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
Small Lymphocytic Lymphoma ◽  
Orphan Designation

Cyclin D1 overexpression in proliferation centres of small lymphocytic lymphoma/chronic lymphocytic leukaemia

2017 ◽  
Vol 70 (10) ◽  
pp. 899-902 ◽  
Author(s):  
Larissa Sena Teixeira Mendes ◽  
Natalie Peters ◽  
Ayoma D Attygalle ◽  
Andrew Wotherspoon
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Cyclin D1 ◽  
Lymphocytic Leukaemia ◽  
Small Lymphocytic Lymphoma

scholarly journals Outcomes of patients with simultaneous diagnosis of chronic lymphocytic leukaemia/small lymphocytic lymphoma and multiple myeloma

2018 ◽  
Vol 185 (2) ◽  
pp. 347-350 ◽  
Author(s):  
Sikander Ailawadhi ◽  
Bhagirathbhai R. Dholaria ◽  
Sharad Khurana ◽  
Taimur Sher ◽  
Victoria Alegria ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
Small Lymphocytic Lymphoma

Chronic lymphocytic leukaemia

2010 ◽  
pp. 4240-4247
Author(s):  
Clive S. Zent ◽  
Aaron Polliack
Keyword(s):  
North America ◽  
Chronic Lymphocytic Leukaemia ◽  
B Lymphocyte ◽  
Lymphocytic Leukaemia ◽  
Immunoglobulin Gene ◽  
Cell Of Origin ◽  
Small Lymphocytic Lymphoma ◽  
Lymphoid Neoplasm ◽  
Surface Immunoglobulin

Chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL) is the most prevalent lymphoid neoplasm in Europe and North America. The ‘cell of origin’ is a mature B lymphocyte that has a rearranged immunoglobulin gene. CLL cells express modest amounts of surface immunoglobulin, and are characterized by defective apoptosis. The cause of CLL is unknown....

scholarly journals Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases

2019 ◽  
Vol 12 (2) ◽  
pp. 69 ◽  
Author(s):  
Daniel A. Rodrigues ◽  
Fernanda S. Sagrillo ◽  
Carlos A. M. Fraga
Keyword(s):  
Clinical Trials ◽  
Follicular Lymphoma ◽  
Chronic Lymphocytic Leukaemia ◽  
Drug Administration ◽  
Small Molecule ◽  
Lymphocytic Leukaemia ◽  
Food And Drug Administration ◽  
Small Lymphocytic Lymphoma ◽  
Dual Inhibitor ◽  
Systemic Therapies

Duvelisib (Copiktra®) is a dual inhibitor of phosphoinositide 3-kinases (PI3Kδ and PI3Kγ). In 2018, duvelisib was first approved by the Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) after at least two prior therapies. Duvelisib has also been approved under accelerated track for relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. In this review, we provide a series of information about duvelisib, such as the development of clinical trials for LLC/SLL and FL and the steps used for its synthesis.

Lymphomatoid papulosis associated with chronic lymphocytic leukaemia/small lymphocytic lymphoma: three cases

2017 ◽  
Vol 178 (1) ◽  
Author(s):  
H. Adamski ◽  
S. Ingen‐Housz‐Oro ◽  
L. Machet ◽  
A.C. Carriou ◽  
C. Ram‐Wolff ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
Small Lymphocytic Lymphoma ◽  
Lymphomatoid Papulosis
Sign in / Sign up

Export Citation Format

Share Document